Literature DB >> 8445525

Logarithmic transformation in bioequivalence: application with two formulations of perphenazine.

K K Midha1, E D Ormsby, J W Hubbard, G McKay, E M Hawes, L Gavalas, I J McGilveray.   

Abstract

The rationale for using the logarithmic transformation on concentration-dependent pharmacokinetic parameters a priori is presented. This rationale is based on theoretical pharmacokinetic and statistical grounds, but is also applicable to the practice of physicians in dealing with variations of drug treatment within and between patients. The implications of the transformation on data analysis, specifically analysis of variance, and estimation and inference from the analysis as it pertains to bioequivalence decisions are explored. Implementation of the transformation is shown, with an example of two perphenazine formulations in a single-dose crossover study. It is concluded that the transformation has to be accepted on theoretical grounds because sample sizes are too small in bioequivalence studies and too susceptible to extreme values to state with any certainty the actual distribution of pharmacokinetic parameters or their differences within a subject.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445525     DOI: 10.1002/jps.2600820205

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

1.  Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.

Authors:  B Auclair; D E Nix; R D Adam; G T James; C A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Urinary excretion: does it accurately reflect relative differences in bioavailability/systemic exposure when renal clearance is nonlinear?

Authors:  Gary A Thompson; Roger D Toothaker
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

3.  Comparison of parametric and bootstrap method in bioequivalence test.

Authors:  Byung-Jin Ahn; Dong-Seok Yim
Journal:  Korean J Physiol Pharmacol       Date:  2009-10-31       Impact factor: 2.016

4.  Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations.

Authors:  C J Timmer; J E Paanakker; M Vrijmoed-de Vries
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

5.  Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.

Authors:  F H Noormohamed; M S Youle; C J Higgs; S Martin-Munley; B G Gazzard; A F Lant
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin.

Authors:  F L Degner; G Heinzel; H Narjes; D Türck
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

7.  Effect of antacids in didanosine tablet on bioavailability of isoniazid.

Authors:  K Gallicano; J Sahai; G Zaror-Behrens; A Pakuts
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes.

Authors:  D P Healy; M C Brodbeck; C E Clendening
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

9.  Pharmacokinetics of chlorpromazine and key metabolites.

Authors:  P K Yeung; J W Hubbard; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  A survey of the likelihood approach to bioequivalence trials.

Authors:  Leena Choi; Brian Caffo; Charles Rohde
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.